Executive Summary / Key Takeaways
- Healthcare Realty Trust has completed a fundamental transformation from a transactions-oriented acquisition machine to an operations-focused real estate platform, de-risking the business model while unlocking embedded value in a 13% lease-up portfolio that could deliver $50 million of incremental NOI.
- The company's aggressive $1.2 billion asset disposition program at a 6.7% blended cap rate has repaired the balance sheet, reducing net debt to EBITDA from 6.4x to 5.4x and creating capacity for $300 million of high-return redevelopment investments targeting 10% yields on cost.
- Trading at 10-11x FFO—six turns below both its historical average and healthcare REIT peers—HR's valuation reflects past missteps rather than current fundamentals, offering potential multiple expansion as the 2.0 strategy demonstrates 5% core earnings growth embedded in flat 2026 guidance.
- The lease-up portfolio represents the primary engine of future growth: 95 assets at 70% occupancy with rents 20% below market offer a clear path to 90% occupancy, with management already identifying $15 million of the $50 million NOI upside through active leasing and redevelopment.
- Key risks center on execution of the operational turnaround, interest rate headwinds from refinancing $600 million of 3.5% bonds at low-5% rates in 2026, and healthcare policy shifts, though the pure-play MOB positioning provides insulation from site-neutral payment pressures affecting inpatient facilities.
Setting the Scene: From Transactions to Operations
Healthcare Realty Trust Incorporated, founded in 2005 with its auditor serving continuously since inception, has spent two decades building the largest dedicated outpatient medical real estate portfolio in the United States. Headquartered in Nashville, Tennessee, the company operates as a pure-play medical office building (MOB) REIT, a positioning management describes as a "subsector of one" with no direct public market peers. This specialization became both a strength and a liability: while it created deep expertise in outpatient facilities, the company's "transactions-oriented culture" (Healthcare Realty 1.0) collapsed in 2022 when acquisition-driven growth could no longer support a premium valuation.
The July 2022 merger with Healthcare Trust of America marked an inflection point, creating a 32-million-square-foot behemoth but also revealing the limitations of scale without operational discipline. By 2025, the board recognized that size alone would not drive returns. A comprehensive governance overhaul reduced director count from 12 to 7, with five directors appointed since 2024, bringing fresh perspective alongside institutional knowledge from executives like Robert E. Hull (employed since 2004) and Ryan E. Crowley (since 2006). The appointment of Peter Scott as President and CEO in April 2025 catalyzed Healthcare Realty 2.0, a strategic shift toward an "operations-oriented culture where earnings growth is paramount."
This transformation addresses the fundamental flaw that collapsed the old model: growth through acquisitions at premium valuations creates no value if operational efficiency doesn't improve. The new strategy prioritizes internal capital allocation toward accretive reinvestment in the existing portfolio rather than external deals, a crucial pivot in an environment where private capital has flooded the MOB space, making acquisitions difficult to underwrite. Healthcare systems now represent nearly 50% of leasing activity, up significantly from 2023, reflecting a structural shift where providers seek strategic control over outpatient assets rather than purely financial returns—a dynamic that supports disposition pricing and leasing velocity.
The outpatient medical real estate sector provides a supportive backdrop. For the 17th consecutive quarter, occupancy across the top 100 metros increased toward a record 93%, while new supply remains muted and demand steadily increases. Health systems continue investing robustly in outpatient services as a key component to reduce operating costs and expand market share, creating a durable demand driver. This industry structure means HR's 25 million square feet of stabilized assets operate in a seller's market, while its lease-up portfolio benefits from demand that consistently outstrips supply.
Portfolio Segmentation: Three Paths to Value Creation
Healthcare Realty's strategy hinges on treating its portfolio not as a monolithic whole but as three distinct asset classes requiring different management approaches. This segmentation allows capital allocation to flow toward the highest-return opportunities while divesting assets that drag overall growth.
The Stabilized Core: A 3-4% Growth Engine
The stabilized portfolio comprises 470 properties totaling over 25 million square feet, representing 75% of total assets. With 95% occupancy, NOI margins exceeding 65%, and average lease terms of eight years with 3% escalators, this segment functions as a bond-like core delivering predictable 3-4% annual NOI growth. Pushing this closer to 4% is significant because on a $25 million square foot base, each 100 basis points of additional growth compounds to meaningful value creation over three years. The portfolio's concentration on flagship campuses and trophy properties creates pricing power: 2025 leasing activity achieved 3.1% average escalators, raising the portfolio average to 2.9%, while cash leasing spreads improved 60 basis points to 2.70% and tenant retention reached 82%, up 220 basis points. These metrics demonstrate that operational focus—not acquisition volume—drives lease economics.
The Lease-Up Portfolio: The $50 Million Question
The 95 assets in the lease-up segment, spanning over 7 million square feet in priority markets like Denver, Dallas, and Phoenix, represent HR's primary growth engine despite comprising just 13% of the portfolio. Current occupancy of 70% with NOI margins of 55% and rents nearly 20% below market signal massive embedded value. Management estimates $50 million of incremental NOI upside from moving occupancy to 90%, a target that would transform this drag on overall performance into a meaningful contributor.
The significance lies in the fact that $50 million of additional NOI on a portfolio generating roughly $450 million of annual NOI represents an 11% increase in earnings power, yet the market appears to be valuing HR as if this upside doesn't exist. The capital required—approximately $300 million over three years for ready-to-occupy (RTO) spec suites and redevelopment—will be funded primarily through the rightsized dividend, which frees up $100 million annually for reinvestment. This internal funding avoids dilutive equity issuance at the current compressed valuation.
The RTO program's economics are compelling: projects target mid-teens IRRs with 7-year lease terms, while reducing time from lease execution to cash-paying rent by 6 to 10 months compared to traditional build-to-suit. In Q4 2025, redevelopment properties experienced a 1,000 basis point increase in lease percentage, driven by strong demand including a 64,000 square foot lease with Saint Peter's Health. Management's conviction in this strategy is supported by early results: by year-end 2025, $15 million of the $50 million NOI upside had been identified through leasing activity, representing about a third of the total target. The real benefits will materialize in 2027 and 2028 due to the 12-18 month timeline for redevelopment projects, creating a visible earnings ramp that isn't reflected in flat 2026 guidance.
The Disposition Portfolio: Cleaning House
The 12% of assets designated for disposition—characterized by lower occupancy, lower margins, and older vintage—dragged overall NOI growth by 700 basis points over the prior two years. Selling these properties matters not just for the proceeds but for the removal of a structural headwind. The company executed $1.2 billion of sales at a blended 6.7% cap rate, exceeding the high end of guidance and fully exiting 14 noncore markets. This demonstrates buyer appetite for non-core assets while allowing HR to focus resources on high-growth markets.
The disposition pricing reveals market dynamics: 80% of these assets sat outside priority markets, yet strong buyer demand—fueled by bank debt in the high-4% range and health system acquisitions driven by long-term strategy rather than price sensitivity—allowed HR to achieve better-than-expected pricing. The Richmond, VA portfolio sale at a high-5% cap rate illustrates how health system buyers prioritize control over yield, supporting disposition values. The $900 million in proceeds used to repay debt reduced net debt to EBITDA to 5.4x by year-end, ahead of target and creating modest balance sheet capacity for future capital allocation.
Financial Performance: Evidence of Operational Turnaround
Healthcare Realty's 2025 results validate the 2.0 strategy. Normalized FFO of $1.61 per share exceeded the midpoint of original guidance by $0.03, while same-store NOI growth of 4.8% surpassed guidance by 140 basis points. This outperformance demonstrates that operational improvements are flowing through to earnings faster than the dilution from dispositions. Q4 2025 normalized FFO of $0.40 and same-store cash NOI growth of 5.5% show accelerating momentum, driven by 103 basis points of occupancy gains, 3.7% cash leasing spreads, and continued expense controls.
The income statement reveals the transformation's mechanics. Property operating expenses decreased $24.4 million (5.1%) primarily due to dispositions, while G&A expenses fell $10.6 million (12.7%) from payroll and severance reductions, offsetting incentive compensation increases. This $10 million run-rate G&A savings target was achieved ahead of schedule, demonstrating management's commitment to efficiency. Depreciation and amortization dropped $111.2 million (16.5%) as fully depreciated assets were disposed, while interest expense decreased $33.4 million from term loan repayments. These cost reductions show the operational leverage inherent in focusing on existing assets rather than acquiring new ones.
Impairment charges of $361.1 million in 2025 relate to completed or planned dispositions and changes in holding periods—accounting recognition that the company is jettisoning low-return assets to focus on high-growth opportunities. The cash flow statement tells the real story: operating cash flow of $457.1 million funded $308.8 million in capital expenditures, with $136.6 million allocated to development and redevelopment, $90.2 million to first-generation tenant improvements, and $46.9 million to second-generation improvements. This capital deployment is directed toward the lease-up portfolio where returns are highest.
The balance sheet transformation is equally significant. As of December 31, 2025, 72.5% of principal balances were due after 2027 (including extension options), and debt service coverage of 3.5x exceeded covenant minimums by 2.3x. Total debt to total assets less intangibles of 35.8% sits well below the 60% covenant maximum. This financial flexibility enabled the January 2026 repurchase of 2.9 million shares for $50 million and the February 2026 establishment of a $600 million commercial paper program to diversify capital sources and reduce interest costs relative to the line of credit.
Capital Allocation: A Disciplined Hierarchy
Healthcare Realty 2.0's capital allocation framework represents a radical departure from the acquisition-heavy past. The priorities are clear: first, redeploy capital into existing portfolio redevelopments targeting 10% yields on cost; second, return capital through share buybacks when the stock trades below intrinsic value; third, pursue joint ventures only if they create earnings accretion through investment returns and advantageous fee arrangements. This hierarchy ensures every dollar is allocated to its highest and best use rather than being automatically plowed into dilutive acquisitions.
The $300 million redevelopment commitment over three years—funded primarily by the $100 million annual dividend savings from the 23% reduction to $0.24 quarterly—targets mid-teens IRRs and 7-year lease terms. Average projects cost $10 million or $200-300 per square foot, upgrading older buildings to near-new standards. In 2025, $136.6 million was funded toward development and redevelopment, with two active development projects expected to generate $8 million of stabilized NOI and 23 redevelopment projects targeting nearly $8 million of incremental NOI from five assets added in Q3 alone. This capital efficiency generates higher returns than external acquisitions while de-risking the portfolio.
The $50 million share repurchase in January 2026, with $450 million remaining under authorization, signals management's view that the stock is undervalued. CEO Peter Scott's commentary that HR trades at "somewhere in the 10x to 11x FFO" and "six turns below both our 10-year average and the 10-year average of our healthcare REIT peers" provides a clear valuation anchor. This suggests management will be aggressive with buybacks at current levels, providing downside protection and accretion to per-share metrics.
Outlook and Guidance: The Flat FFO Illusion
Management's 2026 guidance—normalized FFO per share of $1.58 to $1.64 with a $1.61 midpoint—appears underwhelming at first glance, implying flat year-over-year growth. However, this guidance embeds approximately 5% core earnings growth that is being masked by the necessary dilution from back-end weighted 2025 dispositions and deleveraging. The company proactively sacrificed short-term FFO growth to strengthen the balance sheet and position for sustainable long-term expansion.
Same-store cash NOI growth guidance of 3.5% to 4.5% for 2026 reflects management's confidence in pushing four key drivers: escalators (targeting 3%+ on new deals), retention (trending toward mid-80s), absorption (though not matching 2025's 100 basis points), and cash leasing spreads. This demonstrates the operational focus is working—earnings growth is coming from existing assets rather than acquisitions. G&A expense guidance of $43-47 million maintains the $10 million savings achieved in 2025, showing the cost structure is permanently lower.
The guidance excludes any additional acquisitions, developments, or incremental share repurchases, focusing capital uses on the asset-level capital plan and the $50 million already deployed for buybacks. This conservatism shows management is prioritizing execution over growth for growth's sake—a discipline that should ultimately command a higher valuation multiple.
Regarding the $50 million NOI upside from the strategic plan, management clarified that approximately $15 million had been identified through leasing activity by year-end 2025, with benefits building in 2027 and further in 2028 due to the lag between lease signing and commencement. This timeline creates a visible earnings ramp that patient investors can underwrite, while the market's focus on 2026 flat FFO may be missing the medium-term inflection.
Risks: What Could Break the Thesis
The most material risk is execution failure on the lease-up strategy. While management expresses conviction that targeted ROI-driven investments can increase occupancy from 70% to 90%, this represents a 2,000 basis point improvement across 7 million square feet. If local relationships cannot be repaired or if demand in Denver, Dallas, and Phoenix proves weaker than anticipated, the $50 million NOI target could prove elusive. The severity is high because this portfolio represents the primary growth engine; failure here would relegate HR to a low-growth, stabilized portfolio REIT trading at a permanent discount.
Interest rate risk looms large in 2026. The company must refinance $600 million of bonds maturing in August 2026, with guidance assuming a low-5% coupon compared to the existing 3.5% rate. This 150+ basis point increase will incrementally pressure FFO by approximately $9 million annually, partially offsetting lease-up gains. While the commercial paper program provides cheaper short-term funding, the permanent increase in long-term debt costs raises the hurdle rate for all future investments and could limit dividend growth potential.
Healthcare policy changes present a nuanced risk. The "One Big Beautiful Bill Act of 2025" permanently extended Tax Cuts and Jobs Act provisions, but potential site-neutral payment policies or Medicaid cuts could pressure tenant profitability. However, CEO Scott's assessment that HR's assets "tends to be a lower cost setting for services" suggests outpatient facilities may benefit as providers shift lower-acuity services away from hospitals. This highlights HR's defensive positioning relative to inpatient-focused peers, though any broad healthcare spending reductions would eventually impact demand.
The Prospect Medical Holdings bankruptcy in January 2025, while resolved in October with Hartford HealthCare (HHC) assuming leases, exposed tenant concentration risk. The company's revenues are subject to the financial strength of health systems facing reimbursement pressures. A larger tenant failure could create vacancy in the stabilized portfolio, disrupting the 95% occupancy foundation that underpins the entire 2.0 strategy.
Organizational restructuring risk should not be dismissed. CEO Scott admitted he "probably underestimated how difficult" telling employees they could no longer be part of the team would be. While the $10 million G&A savings demonstrate successful rationalization, the human capital risk matters because the asset management platform revamp requires new leadership and a new leasing model to drive ROI. Loss of key personnel could slow execution at a critical juncture.
Competitive Context: Pure-Play Versus Diversified Giants
Healthcare Realty's competitive positioning is defined by its purity. While Welltower (WELL) and Ventas (VTR) offer MOB exposure within diversified portfolios spanning senior housing and post-acute care, HR's exclusive focus allows deeper tenant relationships and specialized development expertise. This enables faster leasing cycles and higher retention—82% in 2025 compared to industry averages in the high-70s—creating more predictable cash flows.
However, this purity creates scale disadvantages. Welltower's $152.8 billion enterprise value and Ventas's $51.7 billion dwarf HR's $10.3 billion, giving them superior access to capital and lower cost of debt. WELL's 2025 revenue growth substantially outpaced HR, while VTR's same-store NOI growth showed more pronounced improvements. Larger peers can outbid HR for acquisitions and fund developments more cheaply, potentially limiting external growth opportunities.
Against SNF-focused peers Omega Healthcare (OHI) and Sabra Health Care (SBRA), HR's outpatient positioning offers superior growth prospects as demographics drive demand for ambulatory services while reimbursement pressures weigh on skilled nursing. OHI's 98.6% gross margin reflects triple-net lease stability, but its growth rates are more moderate. SBRA's acquisition-driven strategy boosted its NOI, but HR's development capabilities targeting 10% yields on cost may generate superior long-term returns.
The key differentiator is HR's development and redevelopment expertise. While competitors focus on acquisitions, HR's in-house capability to deliver heavily pre-leased developments and RTO suites creates a competitive moat. The average $10 million redevelopment project at $200-300 per square foot upgrades older buildings to near-new standards, commanding premium rents and mid-teens IRRs. This allows HR to create value from existing assets rather than competing with private capital for scarce acquisitions, a strategy that should command a premium valuation once proven.
Valuation Context: Compressed Multiple Amid Transformation
At $17.20 per share, Healthcare Realty trades at approximately 10-11x normalized FFO based on the $1.61 per share achieved in 2025. This multiple is significant because management explicitly states it is "six turns below both our 10-year average and the 10-year average of our healthcare REIT peers," reflecting "self-inflicted wounds and a loss of credibility" rather than portfolio quality. The stabilized portfolio's irreplaceable locations on flagship campuses with health system tenants should command a premium, not a discount.
Key valuation metrics provide context: EV/EBITDA of 14.56x compares favorably to WELL's 57.34x, VTR's 23.38x, OHI's 16.65x, and SBRA's 16.58x, suggesting HR trades at a structural discount despite similar asset quality. Price to operating cash flow of 13.39x is reasonable for a REIT, while the 5.99% dividend yield offers income while investors wait for the transformation to be recognized. The high 251% payout ratio reflects the transitional nature of 2025 earnings and should normalize as lease-up NOI materializes.
The balance sheet strength supports valuation: debt-to-equity of 0.89x is manageable, and the reduction in net debt to EBITDA to 5.4x from 6.4x demonstrates credible deleveraging. The $600 million commercial paper program established in February 2026 will reduce interest costs compared to the line of credit, further improving cash flow. With $450 million remaining under share repurchase authorization, management has substantial dry powder to create value through buybacks at what it considers depressed valuations.
Conclusion: The Path to Multiple Expansion
Healthcare Realty 2.0 represents more than a rebranding—it is a fundamental rewiring of how the company creates value. The transformation from acquisition-driven growth to operational excellence has already delivered tangible results: 140 basis points of same-store NOI outperformance, $10 million of permanent G&A savings, and $1.2 billion of strategic dispositions at attractive pricing. Yet the stock trades at a multiple that implies continued execution failure.
The investment thesis hinges on two variables: successful lease-up of the 7 million square foot portfolio to capture the $50 million NOI upside, and recognition by the market that a 10-11x FFO multiple is inappropriate for a company with 95% occupancy stabilized assets and a visible 2027-2028 earnings ramp. The flat 2026 FFO guidance is an illusion—5% core growth is being masked by temporary dilution from deleveraging and interest rate headwinds. As lease-up NOI begins flowing in 2027 and the balance sheet optimization is complete, earnings growth should reaccelerate, driving multiple expansion toward the 16x average of healthcare REIT peers.
The "so what" for investors is clear: HR offers a rare combination of immediate income (6% yield), medium-term earnings growth ($50 million NOI upside), and long-term multiple revaluation (6-turn discount to peers). The primary risk is execution, but the early evidence—$15 million of NOI identified, 1,000 basis points of lease-up in Q4, and 82% tenant retention—suggests management is delivering. For investors willing to look past 2026's flat guidance, Healthcare Realty 2.0 offers a compelling path to 40-50% total returns as earnings grow and the multiple normalizes.
